Good post.
Re your point 2, yes one would think that other cardioprotective (although not synergistic) drugs have already been through this phase, and we could copy their methods.
I'm not happy with important preclinical results, whether good or bad, being withheld until a quarterly.
Ann: Quarterly Activity Report & Appendix 4C, page-60
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.85 |
Change
-0.005(0.27%) |
Mkt cap ! $315.1M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.86 | $1.85 | $26.00K | 14.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3574 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 500 | 1 |
View Market Depth
| Last trade - 10.08am 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |